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The midbrain to pons ratio
A simple and specific MRI sign of progressive supranuclear palsy
ABSTRACT
Objectives: MRI-based measurements used to diagnose progressive supranuclear palsy (PSP) typi-
cally lack pathologic verification and are not easy to use routinely. We aimed to develop in histolog-
ically proven disease a simple measure of the midbrain and pons on sagittal MRI to identify PSP.
Methods: Measurements of the midbrain and pontine base on midsagittal T1-weighted MRI were
performed in confirmed PSP (n 5 12), Parkinson disease (n 5 2), and multiple system atrophy
(MSA) (n 5 7), and in controls (n 5 8). Using receiver operating characteristic curve analysis,
cutoff values were applied to a clinically diagnosed cohort of 62 subjects that included PSP
(n 5 21), Parkinson disease (n 5 10), MSA (n 5 10), and controls (n 5 21).
Results: The mean midbrain measurement of 8.1 mm was reduced in PSP (p, 0.001) with reduc-
tion in the midbrain to pons ratio (PSP smaller than MSA; p , 0.001). In controls, the mean
midbrain ratio was approximately two-thirds of the pontine base, in PSP it was ,52%, and in
MSA the ratio was greater than two-thirds. A midbrain measurement of ,9.35 mm and ratio of
0.52 had 100% specificity for PSP. In the clinically defined group, 19 of 21 PSP cases (90.5%)
had a midbrain measurement of ,9.35 mm.
Conclusions: We have developed a simple and reliable measurement in pathologically confirmed
disease based on the topography of atrophy in PSP with high sensitivity and specificity that
may be a useful tool in the clinic. Neurology 2013;80:1856–1861
GLOSSARY
MSA 5 multiple system atrophy; PD 5 Parkinson disease; PSP 5 progressive supranuclear palsy.
Neurodegenerative diseases presenting with parkinsonism including idiopathic Parkinson dis-
ease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) can be dif-
ficult to differentiate clinically particularly early in the disease course.1 Characteristic midbrain
atrophy in PSP and pontine atrophy in MSA can be assessed on MRI2; however, many magnetic
resonance–based measurements proposed as diagnostic for PSP or MSA lack pathologic verifi-
cation and are often not easy to apply routinely.3–9
Our hypothesis was that simple measurements of the midbrain and pons (or their ratio) on
midsagittal MRI would identify confirmed PSP and MSA.
METHODS Standard protocol approvals, registrations, and patient consents. A pathologically confirmed cohort of PSP, PD, and
MSA subjects (table 1) was selected from the Queen Square Brain Bank at UCL Institute of Neurology; brains were donated following ethically
approved protocols under license from the Human Tissue Authority. A cohort of PSP, PD, MSA, and healthy subjects was prospectively
recruited at the National Hospital for Neurology and Neurosurgery, as part of an ethically approved study with written informed consent.
Participants and protocols. In the pathologically confirmed group, the diagnosis was determined using standard neuropathologic
criteria.10 In the clinically diagnosed group, participants fulfilled operational criteria11–13 and were assessed with clinimetric scales
including Hoehn and Yahr,14 the Unified Parkinson’s Disease Rating Scale,15 Folstein Mini-Mental State Examination,16 the Frontal
From the Sara Koe PSP Research Centre (L.A.M., D.C.P., S.S.O., H.L., J.H., T.R., A.J.L.), Rita Lila Weston Institute for Neurology Studies and
Queen Square Brain Bank, Department of Molecular Neurosciences, UCL Institute of Neurology, London, UK; Department of Brain Repair and
Rehabilitation (H.R.J., T.Y., C.M.), UCL Institute of Neurology and Lysholm Department of Neuroradiology, National Hospital for Neurology
and Neurosurgery, Queen Square, London; Dementia Research Centre (N.C.F.), UCL Institute of Neurology, London; Van Cleef Roet Centre for
Nervous Diseases (D.R.W.), Monash University, Melbourne, Australia; Forensic Psychiatry Research Unit (C.K.), Queen Mary, University of
London; and Institute for Ageing and Health (D.J.B.), Newcastle University, Newcastle upon Tyne, UK.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
1856 © 2013 American Academy of Neurology
Assessment Battery,17 Golbe Progressive Supranuclear Palsy Rat-
ing Scale,18 or the Unified Multiple System Atrophy Rating
Scale.19 Healthy controls had no history of neurologic illness at
the time of imaging (figure 1).
In the pathologically confirmed group, cases were selected in
which conventional 1.5-tesla, midsagittal, T1-weighted images
were electronically available. In the clinically diagnosed group,
all had 3-tesla MRI with volumetric T1-weighted images.
Midbrain and pons measurements and the midbrain to
pons ratio. The measurements were taken as described in
figure 2. The midbrain to pons ratio was derived by dividing the
midbrain by the pons measurements. In the pathologically con-
firmed group (n5 29), measurements were made blinded to clinical
and pathologic information (C.M., neuroradiologist); a randomly
chosen subset (n 5 8) was measured by another rater (N.F., neu-
rologist) for interrater assessment. In the clinically diagnosed group
(n 5 62), a third rater (L.M., neurology trainee) performed all
measurements.
Statistical analysis. Group characteristics were compared using
multivariate analysis with post hoc Bonferroni correction. An in-
traclass correlation coefficient was used to assess interrater agree-
ment and receiver operating characteristic curve analysis to define
cutoff values (maximal sum of sensitivity and specificity) in the
pathologically confirmed group that were subsequently applied
to the clinical group. Pearson correlation coefficient was used to
assess correlation of the midbrain measurement and ratio with
age at onset, age at scan, and disease duration in the pathologically
confirmed group, and in the clinically diagnosed group clinical
scores. SPSS 20.0 (IBM SPSS Statistics, Armonk, NY) for Mac
was used for statistical analysis.
RESULTS The demographic features of both cohorts
are described in table 1. In pathologically confirmed
PSP, the mean midbrain measurement and the mid-
brain to pons ratio were significantly smaller than in
controls and MSA; in the MSA group, there was a
trend for the pons measurement to be smaller than
in controls. Additionally, in the clinically diagnosed
group, the pons was significantly smaller and the mid-
brain to pons ratio was significantly increased in MSA
relative to PSP, to PD, and to controls (table 2,
figure 3). Single-measure, intraclass correlation coef-
ficients were 0.97 for the midbrain measurement and
0.94 for the pontine measurement (p , 0.001 for
both).
Defined by the maximum sum of sensitivity and
specificity from the receiver operating characteristic
curve in pathologically confirmed cases, a midbrain
Table 1 Demographic and clinimetric features of the pathologically confirmed and clinically diagnosed
groupsa
Measurement Control PSP PD MSA ANOVA
Pathologically confirmed group
No. 8 12 2 7 —
Age at scan, y 66.8 (8.5) 69.5 (5.0) 70.5 (6.2) 58.4 (5.2)b MSA , PSP (p , 0.001);
MSA , PD (p , 0.05)
Disease duration at scan, y — 3.9 (2.4) 10.7 (9.4) 5.6 (2.9) NS
Clinically diagnosed group
No. 21 21 10 10 —
Age at scan, y 65.9 (5.6) 69.4 (6.5) 66.6 (6.0) 63.4 (8.2) NS
Disease duration, y — 4.6 (3.1) 7.3 (4.1) 4.9 (2.1) NS
H&Y — 3.8 (0.8)b 2.2 (0.8) 4.1 (0.7)b PSP and MSA . PD (p , 0.001)
UPDRS-I — 3.5 (1.9) 2.6 (1.6) 3.4 (1.7) NS
UPDRS-II — 20.5 (7.5)b 10.2 (4.7) 26.7 (6.1)b PSP and MSA . PD (p , 0.001)
UPDRS-III — 38.6 (12.0)b 23.9 (9.3) 52.0 (9.4)b PSP . PD (p 5 0.003);
MSA . PD (p , 0.001);
MSA . PSP (p 5 0.008)
MMSE — 27.5 (2.3) 28.9 (1.2) 28.8 (1.0) NS
FAB — 12.5 (4.3)b 17.0 (0.9) 16.0 (1.7) PSP , PD (p 5 0.003);
PSP , MSA (p 5 0.025)
PSPRS — 38.5 (11.7) — — —
UMSARS — — — 54.9 (12.4) —
Abbreviations: ANOVA 5 analysis of variance; FAB 5 Frontal Assessment Battery; H&Y 5 Hoehn and Yahr; MMSE 5 Mini-
Mental State Examination; MSA 5 multiple system atrophy; NS 5 not significant; PD 5 Parkinson disease; PSP 5 pro-
gressive supranuclear palsy; PSPRS 5 Progressive Supranuclear Palsy Rating Scale; UMSARS 5 Unified Multiple System
Atrophy Rating Scale; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
aData are mean (SD). In the clinical cohort, 17 of 21 were probable and 4 of 21 possible PSP and 7 of 10 MSA were
probable, 3 of 10 possible by research criteria. Eight of 10 MSA cases were of the parkinsonian predominant phenotype in
the clinically diagnosed group.
bStatistically significant differences (ANOVA).
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measurement of ,9.35 mm had 83% sensitivity,
100% specificity, and positive predictive value for
PSP (area under the curve 0.94; p 5 0.002), and a
ratio of,0.52 had 67% sensitivity, 100% specificity,
and positive predictive value for PSP (area under the
curve 0.95; p 5 0.001) when compared with MSA
(figure 3).
In the clinically diagnosed PSP group, a threshold
of 9.35 mm for midbrain diameter had 100% speci-
ficity and positive predictive value for PSP and only 2
cases are not classified as PSP (2/21 5 9.5%). Out-
liers included 1 probable PSP with a disease duration
of 3.7 years and 1 possible PSP with a disease dura-
tion of 4.7 years. For a diagnosis of PSP using a thresh-
old of 0.52 for the midbrain to pons ratio, there was a
specificity and positive predictive value of 100% and
sensitivity of 85.7%.
No correlation was found between age, disease
duration, or clinimetric scores with the midbrain or
pons measurements or ratio.
Figure 1 Flow diagram in the pathologically confirmed group (A) and application of cutoff values to the
clinically defined group (B)
MSA 5 multiple system atrophy; PD 5 Parkinson disease; PSP 5 progressive supranuclear palsy; ROC 5 receiver operating
characteristic.
Figure 2 Measuring the anterior-posterior distance of the pons and midbrain
(A)MidsagittalT1imageonconventionalMRI. (B)Ellipticalregionsof interestwereplacedoverthepons
and themidbrain in themidsagittal slice. Two linesweredrawn todefine themajor axesof the ellipses,
correspondingtoobliquesuperior-inferioraxes (thinwhite lines).Themaximalmeasurementperpendic-
ular to the major axis was taken (thick white lines). In all cases, the posterior border of the pons was
clearly identifiable and did not include the pontine tegmentum; the midbrain measurement did not
include the collicular plate andwas chosen tomaximize the chance of detecting atrophyof this region
in progressive supranuclear palsy as exhibited by the concave appearance in themidsagittal plane.7
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Table 2 Measurements in the pathologically confirmed and clinically diagnosed groupsa
Measurement Control PSP PD MSA ANOVA
Pathologically confirmed group
Midbrain 11.5 (0.4) 8.1 (1.2)b 10.1 (0.8) 10.7 (0.7) PSP , control and MSA (p , 0.001)
Pons 18.2 (0.9) 17.4 (1.8) 17.8 (0.0) 15.5 (2.4) MSA , control (p 5 0.061)
Midbrain to pons ratio 0.63 (0.03) 0.47 (0.08)b 0.57 (0.05) 0.70 (0.11) PSP , control and MSA (p , 0.001)
Clinically diagnosed group
Midbrain 11.1 (0.8) 7.55 (1.12)b 11.4 (0.7) 10.8 (0.8) PSP , control, PD, MSA (p , 0.001)
Pons 17.8 (1.4) 17.1 (1.4) 18.3 (1.1) 14.8 (3.3)b MSA , PSP (p , 0.001);
MSA , PD and control (p , 0.05)
Midbrain to pons ratio 0.62 (0.05) 0.44 (0.08)b 0.63 (0.05) 0.77 (0.18)b PSP , control, PD, MSA (p , 0.001);
MSA . PSP (p , 0.001);
MSA . PD and control (p , 0.05)
Abbreviations: ANOVA5 analysis of variance; MSA5multiple system atrophy; PD5 Parkinson disease; PSP5 progressive
supranuclear palsy.
aData are mean (SD) and measurements are in millimeters.
bStatistically significant differences (ANOVA).
Figure 3 Scatterplots of the midbrain and pons measurements showing both pathologically confirmed and clinically diagnosed groups, and
receiver operating characteristic curve analysis in the pathologically confirmed group comparing PSP and MSA
MSA 5 multiple system atrophy; PD 5 Parkinson disease; PSP 5 progressive supranuclear palsy.
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DISCUSSION We found that in normal controls the
midbrain tegmentum was approximately two-thirds
of the pontine base, whereas in PSP it was half or less
of the pontine base and in MSA it was greater than
two-thirds (table 2, figure 3). All non-PSP subjects
had a midbrain to pons ratio.52%; 67% (patholog-
ically confimed PSP) and 86% (clinically diagnosed
PSP) had a ratio of ,52%. There was excellent
interrater reliability in the measures.
The strengths of our study lie in the pathologic
validation of the diagnosis and the rationalized
approach to developing simple measurement based
on knowledge of the pathologic topography measured
on readily available, conventional, midsagittal MRI.
Although there was a relatively small sample size
of the pathologically confirmed group, our findings
appeared to be confirmed in a larger, albeit clinically
diagnosed, cohort.
The midbrain measurement and midbrain to pons
ratio are approximately equivalent in terms of area
under the curve in predicting the diagnosis: the mid-
brain measurement has higher sensitivity but the ratio
controls for head size, which is a confounding factor of
simpler measurements. Furthermore, a ratio is easier to
estimate using visual inspection. Previous work has
shown the hummingbird sign to be a useful indicator
of midbrain atrophy in PSP.2,4 Midsagittal images are
more reliably reproducible than axial images and linear
measurements,3 and manual segmentation for mea-
surement of area4,5 has been studied in clinically diag-
nosed cases. Our midsagittal midbrain measurement
performed better than qualitative visual assessment
where a hummingbird sign may be seen in only
67%.2 Furthermore, our results compare favorably
with previous reports of midsagittal linear measure-
ments,9 area measurements,5,20 and more detailed anal-
ysis of the area of the midbrain tegmentum.4,21
Our results support the hypothesis that because of
differential patterns of atrophy, a simple ratio mea-
surement of midbrain to pons helps in differentiating
PSP and MSA (figure 3). This is part of the rationale
used in the Magnetic Resonance Parkinson Index.6
A previous study has reported a correlation of dis-
ease severity with midsagittal midbrain area and a
midbrain to pons area ratio5 but other studies using
linear measurements do not report this.4,628 It may be
too much to expect correlation of linear measure-
ments with disease severity—others reported that
midsagittal midbrain area measurements do not cor-
relate with disease severity, although a 3-dimensional
technique may be helpful.20,22
Although promising, this method will need to be
corroborated in larger cohorts and also assessed in
early disease where diagnostic uncertainty is greatest.
Ideally, these studies would also include pathologic
confirmation.
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